Abstract
Glioblastoma (GBM) is the most common type of primary malignant brain tumor. Despite advances in surgical resection, radiotherapy and chemotherapy, prognosis remains very poor. Accordingly, recent studies have been focused on the aberrant signal transduction pathways in glioblastoma. Many patient derived primary glioblastomas and cell lines express constitutively activated signal transducers and activators of transcription 3 (STAT3). Here we focused on the recent progresses regarding to the roles of STAT3 in glioblastoma and glioblastoma stem cells (GBM-SCs), the dysregulation of STAT3 in glioblastoma, and targeting STAT3 for glioblastoma therapy.
Keywords: Cytokine, glioblastoma, glioblastoma stem cells, growth factor, STAT3, STAT3 inhibitor.
Anti-Cancer Agents in Medicinal Chemistry
Title: STAT3 as a Therapeutic Target for Glioblastoma
Volume: 10 Issue: 7
Author(s): Yan Liu, Chenglong Li and Jiayuh Lin
Affiliation:
Keywords: Cytokine, glioblastoma, glioblastoma stem cells, growth factor, STAT3, STAT3 inhibitor.
Abstract: Glioblastoma (GBM) is the most common type of primary malignant brain tumor. Despite advances in surgical resection, radiotherapy and chemotherapy, prognosis remains very poor. Accordingly, recent studies have been focused on the aberrant signal transduction pathways in glioblastoma. Many patient derived primary glioblastomas and cell lines express constitutively activated signal transducers and activators of transcription 3 (STAT3). Here we focused on the recent progresses regarding to the roles of STAT3 in glioblastoma and glioblastoma stem cells (GBM-SCs), the dysregulation of STAT3 in glioblastoma, and targeting STAT3 for glioblastoma therapy.
Export Options
About this article
Cite this article as:
Liu Yan, Li Chenglong and Lin Jiayuh, STAT3 as a Therapeutic Target for Glioblastoma, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (7) . https://dx.doi.org/10.2174/187152010793498636
DOI https://dx.doi.org/10.2174/187152010793498636 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exogenous Expression of WNT7A in Leukemia-Derived Cell Lines Induces Resistance to Chemotherapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry Design Potential Selective Inhibitors for Treating Cancer by Targeting the Src Homology 2 (SH2) Domain-Containing Phosphatase 2 (Shp2) with Core Hopping Approach
Protein & Peptide Letters Therapeutic Hypothermia as a Neuroprotective Strategy in Neonatal Hypoxic-Ischemic Brain Injury and Traumatic Brain Injury
Current Molecular Medicine Microbiology of the Human Intestinal Tract and Approaches for Its Dietary Modulation
Current Pharmaceutical Design Germinal and Somatic Trisomy 21 Mosaicism: How Common is it, What are the Implications for Individual Carriers and How Does it Come About?
Current Genomics Current Understanding of the Interplay Between Catechol-OMethyltransferase Genetic Variants, Sleep, Brain Development and Cognitive Performance in Schizophrenia
CNS & Neurological Disorders - Drug Targets Efficacy of Therapy with c-Met/HGF Inhibitors in Solid Tumors: A Systematic Review Based on 24 Clinical Trials
Clinical Cancer Drugs The Use of Structural Biology in Janus Kinase Targeted Drug Discovery
Current Drug Targets Pharmacometrics of Stilbenes: Seguing Towards the Clinic
Current Clinical Pharmacology Circulatory Estrogen Level Protects Against Breast Cancer in Obese Women
Recent Patents on Anti-Cancer Drug Discovery Of Man in Mouse: Modelling Human Cancer Genotype-Phenotype Correlations in Mice
Current Genomics Experimental Onco-Immunology Revisited
Current Cancer Therapy Reviews Potential Pathways for CNS Drug Delivery Across the Blood-Cerebrospinal Fluid Barrier
Current Pharmaceutical Design subject Index To Volume 2
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Differentiation Potential of Human Retinoblastoma Cells
Current Pharmaceutical Biotechnology Bacteria and Bacterial Toxins as Therapeutic Agents for Solid Tumors
Current Cancer Drug Targets The Role of microRNAs in the Pathogenesis and Treatment of Hematopoietic Malignancies
Current Pharmaceutical Design Lifestyle Factors and Endothelial Function
Current Vascular Pharmacology CAM Use in Pediatric Oncology
Current Pediatric Reviews Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets